We are glad to announce that our adventure in the european PCP tender published by the DECIPHER consortium is continuing.

The consortium we leads scored a 1st place (overall result), among 9 consortia admitted to Phase I and will then continue to DECIPHER PCP Phase II.

We’ll compete with 5 other groups and we will work on the first prototype of the platform. More information is available in the DECIPHER newsletter.

 

About the consortium

The consortium is a partnership between Nextage and  Camelot Biomedical Systems, an hi-tech company based in Genoa.

About DECIPHER

DECIPHER-PCP   aims to develop a mobile solution which enables secure cross-border access to existing patient healthcare portals, with a particular focus on patients with diabetes.